PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 15

Complete if Known	
Application Number	10/048,033
Filing Date	November 28, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1015~~ 1623
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	1	ABRAHAM et al. "Synthesis and biological activity of aromatic amino acid phosphoramidates of 5-fluoro-2'-deoxyuridine and 1-β-arabinofuranosylcytosine: Evidence of phosphoramidase activity" *J. Med. Chem.* (1996) **39**:4569-4575	
	2	AKDAS et al. "Glutathione S-transferase and multidrug-resistant phenotype in transitional cell carcinoma of the bladder" *Eur. Urol.* (1996) **29(4)**:483-486	
	3	ALMASAN et al. "Genetic instability as a consequence of inappropriate entry into and progression through S-phase" *Cancer Metast. Rev.* (1995) **14**:59-73	
	4	ANDERSEN et al. "Detection of C-ERBB-2 related protein in sera from breast cancer patients" *Acta Oncol.* (1995) **34(4)**:499-504	
	5	ANGLADA et al. "*N,N'*-cyclization of carbodiimides with 2-(bromomethyl)acrylic acid. A direct entry to the system 5-methylene-6*H*-pyrimidine-2,4-dione, A new class of thymine analogues" *J. Heterocyclic Chem.* (July-Aug. 1996) **33**:1259-1270	
	6	ANTELMAN et al. "Inhibition of tumor cell proliferation in vitro and in vivo by exogenous $p110^{RB}$, the retinoblastoma tumor suppressor protein" *Oncogene* (1995) **10**:697-704	
	7	ASAKURA and ROBINS, "Cerium(IV) catalyzed iodination at C5 of uracil nucleosides" *Tetrahedron Lett.* (1988) **29(23)**:2855-2858	
	8	ASAKURA and ROBINS "Cerium(IV)-mediated halogenation at C-5 of uracil derivatives" *J. Org. Chem. (1990)* **55**:4928-4933	
	9	AUISI et al. "Comparison of the antiviral effects of 5-methoxymethyldeoxyuridine-5'-monophosphate with adenine arabinoside-5'-monophosphate" *Antivir. Res.* (1983) **3**:161-174	
	10	BAGSHAWE "Antibody-directed enzyme prodrug therapy: A review", *Drug Develop. Res.* (1995) **34(2)**:220-230	
	11	BAJETTA et al. "A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease" *Tumori* (1996) **82**:450-452	
	12	BALZARINI et al. "Incorporation of 5-substituted pyrimidine nucleoside analogues into DNA of a thymidylate synthetase-deficient murine FM3A carcinoma cell line" *Meth. Find. Exp. Clin. Pharmacol.* (1985) **7(1)**:19-28	
	13	BALZARINI et al. "Thymidylate synthase is the principal target enzyme for the cytostatic activity of (*E*)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene" *Mol. Pharmacol.* (1987) **32**:410-416	

Examiner's Signature	L. E. Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 15

Complete if Known	
Application Number	10/048,033
Filing Date	November 28, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1615~~ 1623
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	14	BALZARINI et al. "Differential mechanism of cytostatic effect of (*E*)-5-(2-bromovinyl)-2'-deoxyuridine , 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2" *J. Biol. Chem.* (1993) **268(9)**:6332-6337	
	15	BALZARINI et al. "Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109" *Biochem. Biophy. Res. Co.* (1996) **225**:363-369	
	16	BALZARINI et al. "Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus" *FEBS Lett.* (1997) **410**:324-328	
	17	BANERJEE et al. "Molecular mechanisms of resistance to antifolates, a review" *Acta Biochim. Pol.* (1995) **42(4)**:457-464	
	18	BANERJEE et al. "Role of E2F-1 in chemosensitivity" *Cancer Res.* (Oct. 1, 1998) **58**:4292-4296	
	19	BARBATO, et al. "Synthesis of bridged pyrimidine nucleosides and triazo [4,3-c] pyrimidine nucleoside analogues" *Nucleos. Nucleot.* (1991) **10(4)**:853-866	
	20	BARBOUR et al. "A naturally occurring tyrosine to histidine replacement at residue 33 of human thymidylate synthase confers resistance to 5-fluoro-2'-deoxyuridine in mammalian and bacterial cells" *Mol. Pharmacol.* (1992) **42**:242-248	
	21	BARR "Inhibition of thymidylate synthetase by 5-alkynyl-2'-deoxyuridylates" *J. Med. Chem.* (1981) **24(12)**:1385-1388	
	22	BARR et al. "Thymidylate synthetase-catalyzed conversions of *E*-5-(2-bromovinyl)-2'-deoxyuridylate" *J. Biol. Chem.* (1983) **258(22)**:13627-13631 (Nov. 25, 1983)	
	23	BARR et al. "Reaction of 5-ethynyl-2'-deoxyuridylate with thiols and thymidylate synthetase" *Biochemestry* (1983) **22**:1696-1703	
	24	BARRETT "Trapping of the C5 methylene intermediate in thymidylate synthase" *J. Am. Chem. Soc.* (1998) **120**:449-450	
	25	BENZARIA et al. "Synthesis, *in vitro* antiviral evaluation, and stability studies of bis(*S*-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability" *J. Med. Chem.* (1996) **39**:4958-4965	

Examiner's Signature	L. E. Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 15

Complete if Known	
Application Number	10/048,033
Filing Date	November 28, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1615~~
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS); title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	26	BERGSTROM et al. "C-5-substituted pyrimidine nucleosides. 3. Reaction of allylic chlorides, alcohols, and acetates with pyrimidine nucleoside derived organopalladium intermediates" *J. Org. Chem.* (1981) **46(7)**:1432-1441	
	27	BERGSTROM et al. "Synthesis of (*E*)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine and related analogues: Potent and unusually selective antiviral activity of (*E*)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine against herpes simplex virus type 1" *J. Med. Chem.* (1984) **27**:279-284	
	~~28~~	~~BERKOW et al. (eds), The Merck Manual of Diagnosis and Therapy~~, 16th Edition, Merck & Co., Rahway, NJ, (May 1992) only page 1278 supplied	
	29	BERTINO et al. "Resistance mechanisms to methotrexate in tumors" *Stem Cells* (1996) **14**:5-9	
	30	BIGGE et al. "Palladium-catalyzed coupling reactions of uracil nucleosides and nucleotides" *J. Amer. Chem. Soc.* (Mar. 12, 1980) **102(6)**:2033-2038	
	31	BLACKLEDGE "New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex')" *British J. Cancer* (1998) **77(Supp 2)**:29-37	
	32	BOSSLET et al. "A novel one-step tumor-selective prodrug activation system" *Tumor Targeting* (1995) **1**:45-50	
	33	BOSSLET et al. "Elucidation of the mechanism enabling tumor selective prodrug monotherapy" *Cancer Res.* (Mar 15, 1998) **58**:1195-1201	
	34	BRISON "Gene amplification and tumor progression" *Biochim. Biophys. Acta* (1993) **1155**:25-41	
	35	CARL et al. "Protease-activated 'prodrugs' for cancer chemotherapy" *PNAS USA* (April 1980) **77(4)**:2224-2228	
	36	CARRERAS and SANTI "The catalytic mechanism and structure of thymidylate synthase" *Annu. Rev. Biochem.* (1995) **64**:721-762	
	37	CARTER et al. "Humanization of an anti-p185^{HER2} antibody for human cancer therapy" *PNAS USA* (May 1992) **89**:4285-4289	
	38	CAVA and LEVINSON "Thionation reactions of Lawesson's reagents" *Tetrahedron* (1985) **41(22)**:5061-5087	
	39	CHAKRAVARTY et al. "Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin" *J. Med. Chem.* (1983) **26(5)**:638-644	
	40	CHAUDHURI and KOOL "Very high affinity DNA recognition by bicyclic and cross-linked oligonucleotides" *J. Am. Chem. Soc.* (1995) **117**:10434-10442	

Examiner's Signature	L. E. Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

** Duplicate citation: see PTO-892 for citation.

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 15

Complete if Known	
Application Number	10/048,033
Filing Date	November 28, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1615~~
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	41	CHEN et al. "Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene" *Cancer Res.* (Mar. 15, 1996) **56**:1331-1340	
	42	CHO and JOHNSON "(*E*)-5-(3-oxopropen-1-yl)-2'-deoxyuridine and (*E*)-5-(3-oxopropen-1-yl)-2',3'-dideoxyuridine; New antiviral agents: Synthesis and biological activity" *Tetrahedron Lett.* (1994) **35(8)**:1149-1152	
	43	CLARKE "Animal models of breast cancer: Their diversity and role in biomedical research" *Breast Cancer Res. Tr.* (1996) **39**:1-6	
	44	CODERRE et al. "Mechanism of action of 2',5-difluoro-1-arabinosyluracil" *J. Med. Chem.* (1983) **26(8)**:1149-1152	
	45	COLACINO "Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU)" *Antivir. Res.* (1996) **29**:125-139	
	46	COLLINS et al. "Suicide prodrugs activated by Thymidylate synthase: Rationale for treatment and noninvasive imaging of tumors with deoxyuridine analogues" *Clin. Cancer Res.* (August 1999) **5**:1976-1981	
	47	CONNORS "Prodrugs in cancer chemotherapy" *Xenobiotica* (1986) **16(10/11)**:975-988	
	48	CONNORS "Is there a future for cancer chemotherapy?" *Ann. Oncol.* (1996) **7**:445-452	
	49	CONNORS and KNOX "Prodrugs in cancer chemotherapy" *Stem Cells* (1995) **13**:501-511	
	50	COPUR et al. "Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil" *Biochem. Pharmacol.* (1995) **49(10)**:1419-1426	
	51	CRISP "Synthesis of 5-alkenyl-2'-deoxyuridines via organostannanes" *Synth. Commun.* (1989) **19(11 & 12)**:2117-2123	
**	~~52~~	~~DAGLE et al. "Targeted degradation of mRNA in Xenopus oocytes and embryos directed by modified oligonucleotides: Studies of An2 and Cyclin in embryogenesis" *Nucleic Acids Res.* (Aug. 25, 1990) **18(16)**:4751-4757~~	
	53	DALE et al. "The synthesis and enzymatic polymerization of nucleotides containing mercury: Potential tools for nucleic acid sequencing and structural analysis" *PNAS USA* (August 1973) **70(8)**:2238-2242	
	54	DAVISSON et al. "Expression of human thymidylate synthase in *Escherichia coli*" *J. Biol. Chem.* (1989) **264(16)**:9145-9148	
	55	DAVISSON et al. "Expression of human thymidylate synthase in *Escherichia coli*. (Additions and corrections)" *J. Biol. Chem.* (Dec. 2, 1994) **269(48)**:30740	

Examiner's Signature	L. E[Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

** Duplicate citation: see PTO-892 for citation.

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 15

Complete if Known	
Application Number	10/048,033
Filing Date	November 28, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623-~~Not Yet Assigned~~---
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	56	DeCLERCQ et al. "Nucleic acid related compounds. 40. Synthesis and biological activities of 5-alkynyluracil nucleosides" *J. Med. Chem.* (1983) **26**:661-666	
	57	DICKER et al. "Methotrexate resistance in an *in vivo* mouse tumor due to a non-active-site dihydrofolate reductase mutation" *PNAS USA* (Dec. 1993) **90**:11797-11801	
	58	DIRVIN et al. "The role of human glutathione *S*-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thiotepa" *Cancer Res.* (April 15, 1995) **55**:1701-1706	
	59	DORR and von HOFF "PALA" *In*: Cancer Chemotherapy Handbook, 2nd Edition, Appleton & Lange, Norwalk, Connecticut (1994) pp. 768-773	
	60	DUNN, III et al. "Solution of the conformation and alignment tensors for the binding of trimethoprim and its analogs to dihydrofolate reductase: 3D-quantitative structure-activity relationship study using molecular shape analysis, 3-way partial least-squares regression, and 3-way factor analysis" *J. Med. Chem.* (1996) **39**:4825-4832	
	61	DYER et al. "Nucleic Acids Chemistry: Improved and new synthetic procedures, methods, and techniques" Townsend, L. B. & Tipson, R. S., eds. (Wiley-Interscience, New York, NY) (1991) 4:79-83	
	62	ECCLES et al. "Significance of the c-*erbB* family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy" *Invasion Metastasis* (1994-95) **14(1-6)**:337-348	
	63	EISENBRAND et al. "An approach towards more selective anticancer agents" *J. Synthetic Organic Chem.* (1996) **10**:1246-1258	
**	64	EVARD et al. "An *in vitro* nucleoside analog screening method for cancer gene therapy" *Cell Biol. Toxicol.* (1996) **12**:345-350	
	65	EVARD et al. "An in vitro nucleoside analog screening method for cancer gene therapy" *Chem. Abstracts* (1996) **126**:Abstract No. 26514	
	66	FARQUHAR et al. "Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): A strategy to introduce nucleotides into cells" *J. Med. Chem.* (1994) **37**:3902-3909	
	67	FARQUHAR et al. "5'-[4-pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: A membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP)" *J. Med. Chem.* (1995) **38**:488-495	
	68	FARRUGIA et al. "Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex®) in advanced colorectal cancer" *Eur. J. Cancer* (1998) **34(7)**:987-991	
	69	FELIP et al. "Overexpression of c-*erbB*-2 in epithelial ovarian cancer" *Cancer* (Apr. 15, 1995) **75(8)**:2147-2152	
	70	FINCH "Radiation Injury" *In*: Harrison's Principles of Internal Medicine, 12th Edition, McGraw-Hill, Inc., New York, NY (1991) 2204-2208	

Examiner's Signature	L. E. Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

** Duplicate citation: see PTO-892 for citation.

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 15

Complete if Known	
Application Number	10/048,033
Filing Date	November 28, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623---~~1615~~---
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	71	FINER-MOORE et al. "Refined structures of substrate-bound and phosphate-bound thymidylate synthase from *Lactobacillus casei*" *J. Mol. Biol.* (1993) **232**:1101-1116	
	72	FINER-MOORE et al. "Crystal structure of thymidylate synthase from T4 phage: Component of a deoxynucleoside triphosphate-synthesizing complex" *Biochemestry* (1994) **33**:15459-15468	
**	~~73~~	~~FIRESTONE et al. "A comparison of the effects of antitumor agents upon n~~ormal human epidermal keratinocytes and human squamous cell carcinoma" *J. Invest. Dermatol.* (May 1990) **94(5)**:657-661	
	74	FIRESTONE et al. "A comparison of the effects of antitumor agents upon normal human epidermal keratinocytes and human squamous cell carcinoma" *Chem Abstracts* (1990) **113**:Abstract No. 254	
	75	FREED et al. "Evidence for acyloxymethyl esters of pyrimidine 5'-deoxyribonucleotides as extracellular sources of active 5'-deoxyribonucleotides in cultured cells" *Biochem. Pharmacol.* (1989) **38(19)**:3193-3198	
	76	FRIES et al. "Synthesis and biological evaluation of 5-fluoro-2'-deoxyuridine phosphoramidate analogs" *J. Med. Chem.* (1995) **38(14)**:2672-2680	
	77	GARRETT et al. "Thymidylate synthetase. Catalysis of dehalogenation of 5-bromo-and 5-iodo-2'-deoxyuridylate" *Biochemistry* (1979) **18(13)**:2798-2804	
	78	GOLDBERG et al. "Novel cell imaging techniques show induction of apoptosis and proliferation in mesothelial cells by asbestos" *Am. J. Respir. Cell Mol. Biol.* (1997) **17**:265-271	
	79	GOLDSTEIN and BROWN "Genetic aspects of disease" *In*: Harrison's Principles of Internal Medicine, 12th Edition, McGraw-Hill, Inc., New York, NY (1991) pp. 21-76	
	80	GOODWIN et al. "Incorporation of alkylthiol chains at C-5 of deoxyuridine" *Tetrahedron Lett.* (1993) **34(35)**:5549-5552	
	81	GOTTESMANN et al. "Genetic analysis of the multidrug transporter" *Annu. Rev. Genet.* (1995) **29**:607-649	
	82	GRAHAM et al. "DNA duplexes stabilized by modified monomer residues: Synthesis and stability" *J. Chem. Soc. Perkin Trans.* (1998) **1**:1131-1138	
	83	GROS et al. "Isolation and expression of a complementary DNA that confers mutidrug resistance" *Nature* (Oct. 1986) **323**:728-731	
	84	GROS et al. "Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins" *Cell* (Nov. 7, 1986) **47**:371-380	
	85	GROS et al. "Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells" *PNAS USA* (Jan. 1986) **83**:337-341	
	86	GUDKOV et al. "Cloning and characterization of DNA sequences amplified in multidrug-resistant djungarian hamster and mouse cells" *Somat. Cell Mol. Genet.* (1987) **13(6)**:609-619	

Examiner's Signature	L. E. Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

** Duplicate Citation: See PTO-892 for citation.

10/048,033 - PTO-1449 #3 COPY FOR [ ] File [X] Applicant

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 15

Complete if Known	
Application Number	10/048,033
Filing Date	November 28, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1615~~
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	87	HANDFIELD and LEVESQUE "Strategies for isolation of in vitro expressed genes from bacteria" *FEMS Microbiol. Revs.* (1999) **23**:69-91	
**	~~88~~	~~HAKIMELAHI et al. "Design, synthesis and structure-activity relationship~~ of novel dinucleotide analogs as agents against herpes and human immunodeficiency viruses" "*J. Med. Chem.* (Nov. 10, 1995) **38(23)**:4648-4659	
	89	HARDY et al. "Atomic structure of thymidylate synthase: Target for rational drug design" *Science* (Jan. 23, 1987) **235**:448-455	
	90	HARRIS et al. "Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein" *Cancer Gene Ther.* (1996) **3(2)**:121-130	
	91	HASHIMOTO et al. "Simple separation of tritiated water and [^{3}H]deoxyuridine from [5-^{3}H]deoxyuridine 5'-monophosphate in the thymidylate synthase assay" *Anal. Biochem.* (1987) **167**:340-346	
	92	HEIDELBERGER et al. "Fluorinated pyrimidines and their nucleosides" *Adv. Enzymol. Related Areas Mol. Biol.* (1983) **54**:57-119	
	93	HENGSTSCHLÄGER et al. "The role of p16 in the E2F-dependent thymidine kinase regulation" *Oncogene* (1996) **12**:1635-1643	
	94	HOBBS, Jr. "Palladium-catalyzed synthesis of alkynylamino nucleosides. A universal linker for nucleic acids" *J. Org. Chem.*)1989) **54**:3420-3422	
	95	HORIKOSHI et al. "Quantitation of thymidylate synthase, dihydrofloate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction" *Cancer Res.* (Jan. 1, 1992) **52**:108-116	
	96	HORN et al. "Fialuridine is phosphorylated and inhibits DNA synthesis in isolated rat hepatic mitochondria" *Antivir. Res.* (1997) **34**:71-74	
	97	HOSTETLER et al. "Enhanced oral absorption and antiviral activity of 1-O-octadecyl-*sn*-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, *in vitro*" *Biochem. Pharmacol.* (1997) **53**:1815-1822	
	98	HOUZE, et al. "Detection of thymidylate synthase gene expression levels in formalin-fixed paraffin embedded tissue by semiquantitative, nonradioactive reverse transcriptase polymerase chain reaction" *Tumor Biol.* (1997) **18**:53-68	
	99	HSAIO and BARDOS "Synthesis of 5'-thymidinyl bis(1-aziridinyl)phosphinates as antineoplastic agents" *J. Med. Chem.* (1981) **24**:887-889	

Examiner's Signature	L. EY Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

** Duplicate citation: see PTO-892 for citation.

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	8	of	15

Complete if Known	
Application Number	10/048,033
Filing Date	November 28, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1615~~
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	100	HU et al. "Determination of absorption characteristics of AG337, a novel thymidylate synthase inhibitor, using a perfused rat intestinal model" *J. Pharmaceutical Sciences* (July 1998) **87(7)**:886-890	
	101	HUANG and SANTI "Active site general catalysts are not necessary for some proton transfer reactions of thymidylate synthase" *Biochemistry* (1997) **36**:1869-1873	
	102	HUDZIAK et al. "Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor α in NIH 3T3 cells" *PNAS USA* (July 1988) **85**:5102-5106	
	103	HUDZIAK et al. "Selection for transformation and met protooncogene amplification in NIH 3T3 fibroblasts using tumor necrosis factor α" *Cell Growth & Differentiation* (1990) **1**:129-134	
	104	HUSAK et al. "Pseudotumour of the tongue caused by herpes simplex virus type 2 in an HIV-1 infected immunosuppressed patient" *Brit. J. Dermatol.* (1998) **139**:118-121	
	105	IMAI et al. "Studies on phosphorylation. IV. Selective phosphorylation of the primary hydroxyl group in nucleosides" *J. Org. Chem.* (June 1969) **34(6)**:1547-1550	
	106	JACKMAN et al. "Quinazoline-based thymidylate synthase inhibitors: Relationship between structural modifications and polyglutamation" *Anti-Cancer Drug Design* (1995) **10**:573-589	
	107	JOHNSTON et al. "Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue" *Cancer Res.* (Dec. 15, 1991) **51**:6668-6676	
	108	JOHNSTON "The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer" *J. Clin. Oncol.* (Dec. 1994) **12(12)**:2640-2647	
	109	KAMB "Cyclin-dependent kinase inhibitors and human cancer" *Curr. Top. Microbiol. Immunol.* (1998) **227**:139-148	
	110	KASHANI-SABET et al. "Detection of drug resistance in human tumors by *in vitro* enzymatic amplification" *Cancer Res.* (Oct. 15, 1988) **48**:5775-5778	
	111	KATKI et al. "Prodrugs activated by thymidylate synthase: Treatment of tumors with deoxyuridine analogs" *Proc. Amer. Assoc. Cancer Res.* (March 1998) **39**:Abstract No. 1275	
	112	KLECKER et al. "Toxicity, metabolism, DNA incorporation with lack of repair, and lactate production for 1-(2'-fluoro-2'-deoxy-β-D-arabinofuranosyl)-5-iodouracil in U-937 and MOLT-4 cells" *Mol. Pharmacol.* (1994) **46**:1204-1209	
	113	KNIGHTON et al. "Structure of and kinetic channelling in bifunctional dihydrofolate reductase-thymidylate synthase" *Nature Struct. Biol.* (March 1994) **1(3)**:186-194	
	114	KOBAYASHI et al. "Effect of hammerhead ribozyme against human thymidylate synthase on the cytotoxicity of thymidylate synthase inhibitors" *Jpn. J. Cancer Res.* (Nov. 1995) **86**:1014-1018	

Examiner's Signature	E. Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

**

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 15

Complete if Known	
Application Number	10/048,033
Filing Date	November 28, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1615~~
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	115	KODAMA et al. "Evaluation of antiherpetic compounds using a gastric cancer cell line: Pronounced activity of BVDU against herpes simplex virus replication" *Microbiol. Immunol.* (1996) **40(5)**:359-363	
	116	KUMAR et al. "Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives" *J. Med. Chem.* (Sept. 1990) **33(9)**:2368-2374	
	117	KUNDU et al. "Synthesis and biological activities of [E]-5-(2-acylvinyl) uracils" *Eur. J. Med. Chem.* (1993) **28**:473-479	
	118	KUROBOSHI and HIYAMA "A facile synthesis of difluoromethylene compounds by oxidative fluorodesulfurization of dithioacetals using tetrabutylammonium dihydrogentrifluoride and *N*-halo compounds" *SYNLETT* (Dec. 1991) pp. 909-910	
	119	KUROBOSHI and HIYAMA "A facile synthesis of α,α-difluoroalkyl ethers and carbonyl fluoride acetals by oxidative desulfurization-fluorination" *SYNLETT* (April 1994) pp. 251-252	
	120	LAM "Application of combinatorial library methods in cancer research and drug discovery" *Anti-Cancer Drug Design* (1997) **12**:145-167	
	121	LARSSON et al. "Thymidylate synthase in advanced gastrointestinal and breast cancers" *Acta Oncologica* (1996) **35(4)**:469-472	
	122	LASIC "Doxorubicin in sterically stabilized liposomes" *Nature* (Apr. 11, 1996) **380**:561-562	
	123	LEWIS et al. "A serum-resistant cytofection for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA" *PNAS USA.* (April 1996) **93**:3176-3181	
	124	LI et al. "Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines" *PNAS USA* (Oct. 1995) **92**:10436-10440	
	125	LIN et al., "Rhenium188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases" *Eur. J. Nucl. Med.* **24**(6):590-595 (June 1997)	
	126	LIVAK et al. "Detection of single base differences using biotinylated nucleotides with very long linker arms" *Nucl. Acids Res.* (1992) **20(18)**:4831-4837	
	127	LIVINGSTONE et al. "Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53" *Cell* (Sept. 18, 1992) **70**:923-935	
	128	LÖNN et al. "Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy" *Cancer* (Jan. 1, 1996) **77(1)**:107-112	
	129	LOVEJOY et al. "Animal models and the molecular pathology of cancer" *J. Pathol.* (1997) **181**:130-135	

Examiner's Signature	L. E. Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 10 of 15

Complete if Known	
Application Number	10/048,033
Filing Date	November 28, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1615~~
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	130	MASTERS and ALTARDI "The nucleotide sequence of the cDNA coding for the human dihydrofolic acid reductase" *Gene* (1983) **21**:59-63	
	131	McGUIGAN et al. "Certain phosphoramidate derivatives of dideoxy uridine (ddU) are active against HIV and successfully by-pass thymidine kinase" *FEBS Let* (1994) **351**:11-14	
	132	McGUIGAN "Aryl phosphate derivatives of AZT retain activity against HIV1 in cell lines which are resistant to the action of AZT" *Antivir. Res.* (1992) **17**:311-321	
	133	McGUIGAN "Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT" *J. Med. Chem.* (1993) **36**:1048-1052	
	134	McGUIGAN "Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite" *J. Med. Chem.* (1996) **39**:1748-1753	
	135	McGUIGAN et al. "Synthesis and evaluation of some masked phosphate esters of the anti-herpetic drug 882C (netivudine) as potential antiviral agents" *Antivir. Chem. Chemoth.* (1998) **9**:233-243	
	136	McINTEE "Probing the mechanism of action and decomposition of amino acid phosphomonoester amidates of antiviral nucleoside prodrugs" *J. Med. Chem.* (1997) **40**:3323-3331	
	137	McKAY et al. "Broad spectrum aminoglycoside phosphotransferase type III from *Enterococcus*: Overexpression, purification, and substrate specificity" *Biochemistry* (1994) **33**:6936-6944	
	138	MEAD et al. "Pharmacologic aspects of homofolate derivatives in relation to amethopterin-resistant murine leukemia" *Cancer Res.* (Nov. 1966) **26(1)**:2374-2379	
	139	MEDEN et al. "Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy" *J. Cancer Res. Clin. Oncol.* (1994) **120**:378-381	
	140	MEIER et al. "ADA-bypass by lipophilic *cyclo*sal-ddAMP pro-nucleotides a second example of the efficiency of the *cyclo*sal-concept" *Bioorg. Med. Chem. Lett.* (1997) **7(12)**:1577-1582	
	141	MEIER et al. "Cyclic saligenyl phosphotriesters of 2',3'-dideoxy-2',3'-didehydrothymidine (d4T) - a new pro-nucleotide approach" *Bioorg. Med. Chem. Lett.* (1997) **7(2)**:99-104	
	142	MEIER et al. "*Cyclo*Sal-pro-nucleotides: The design and biological evaluation of a new class of lipophilic nucleotide prodrugs" *Int'l. Antiviral News* (1997) **5(10)**:183-185	
	143	MELTON et al. "Antibody-directed enzyme prodrug therapy (ADEPT). Review article" *Drugs of the Future* (1996) **21(2)**:167-181	
	144	MELTON and SHERWOOD "Antibody-enzyme conjugates for cancer therapy" *J. Natl. Cancer Inst.* (Feb. 21, 1996) **88(3/4)**:153-165	
	145	MIDGLEY and KERR "Colorectal cancer" *Lancet* (Jan 30, 1999) **353**:391-399	

Examiner's Signature	L. E. Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 11 of 15

Complete if Known	
Application Number	10/048,033
Filing Date	November 28, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1615~~
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	146	MONTFORT and WEICHSEL "Thymidylate synthase: Structure, inhibition, and strained conformations during catalysis" *Pharmacol. Ther.* (1997) **76(1-3)**:29-43	
	147	MONTGOMERY et al., "Phosphonate analogue of 2'-deoxy-5-fluorouridylic acid" *J. Med. Chem.* (1979) **22(1)**:109-111	
	148	MORGAN et al. "Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione *S*-transferase" *Cancer Res.* (June 15, 1998) **58**:2568-2575	
**	~~149~~	~~MORRISON & BOYD (eds) Organic Chemistry, Allyn~~ & Bacon, Inc., Boston, MA, (1973) only pages 1170-1180 supplied	
	150	MURAKAMI and SEKIYA "Accumulation of genetic alterations and their significance in each primary human cancer and cell line" *Mutat. Res.* (1998) **400(1-2)**:421-437	
**	~~151~~	~~NAESENS et al. "Anti-HIV activity and metabolism of phosphoramidate~~ derivatives of D4T-MP with Variations in the amino acid moiety" Poster Session 1, The Tenth International Conference on Antiviral Research, Hotel Nikko, Atlanta, GA April 6-11, 1997; published in *Antivir. Research* (April 1997) **34(2)**:A54 (Abstract 40)	
	152	NAKANO et al., "Critical role of phenylalanine 34 of human dihydrofolate reductase in substrate and inhibitor binding and in catalysis" *Biochemistry* (1994) **33**:9945-9952	
	153	NICHOL and HAKALA "Comparative growth-inhibitory activity of homofolic aid against cell lines sensitive and resistant to amethopterin" *Biochem. Pharmacol.* (Oct. 1966) **15(10)**:1621-1623	
	154	NOOTER and STOTER "Molecular mechanisms of multidrug resistance in cancer chemotherapy" *Path. Res. Pract.* (1996) **192**:768-780	
	155	OSAKI et al. "5-fluorouracil (5-FU) induced apoptosis in gastric cancer cell lines: Role of the p53 gene" *Apoptosis* (1997) **2**:221-226	
	156	OSHIRO et al. "Genotoxic properties of *(E)*-5-(2-bromovinyl)-2'-deoxyuridine (BVDU)" *Fundam. Appl. Toxicol.* (1992) **18**:491-498	
	157	PARDO et al. "The incorporation of deoxyuridine monophosphate in DNA increases the sister-chromatid exchange yield" *Exp Cell Res.* (1987) **168**:507-517	
	158	PARK et al. "Chemotherapy efficacy of E-5-(2-bromovinyl)-2'-deoxyuridine for orofacial infection with herpes simplex virus type 1 in mice" *J. Infectious Diseases* (June 1982) **145(6)**:909-913	
	159	PERRY et al. "Plastic adaptation toward mutations in proteins: Structural comparison of thymidylate synthases" *Proteins* (1990) **8**:315-333	
	160	PESTALOZZI et al. "Prognostic importance of thymidylate synthase expression in early breast cancer" *J. Clin. Oncol.* (May 1997) **15(5)**:1923-1931	

Examiner's Signature	L. E. Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

** Duplicate citation: see PTO-892 for citation.

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet | 12 | of | 15

Complete if Known	
Application Number	10/048,033
Filing Date	November 28, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1615~~
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	161	PETERS et al. "Thymidylate synthase and drug resistance" *Eur. J. Can.* (1995) **31A(7/8)**:1299-1305	
	162	PHELPS et al. "Synthesis and biological activity of 5-fluoro-2'-deoxyuridine 5'-phosphorodiamidates" *J. Med. Chem.* (1980) **23**:1229-1232	
	163	PUPA et al. "The extracellular domain of the c-*erb*B-2 oncoprotein is released from tumor cells by proteolytic cleavage" *Oncogene* (1993) **8**:2917-2923	
	164	ROBERTS "An isotopic assay for thymidylate synthetase" *Biochemistry* (Nov. 1966) **5(11)**:3546-3548	
	165	ROBINS and BARR "Nucleic acid related compounds. 31. Smooth and efficient palladium-copper catalyzed coupling of terminal alkynes with 5-iodouracil nucleosides" *Tetrahedron Lett.* (1981) **22**:421-424	
	166	ROBINS et al. "Nucleic acid related compounds. 38. Smooth and high-yield iodination and chlorination at C-5 of uracil bases and *p*-toluyl-protected nucleosides" *Can. J. Chem.* (1982) **60**:554-557	
	167	ROBINS and BARR "Nucleic acid compounds. 39. Efficient conversion of 5-iodo to 5-alkynyl and derived 5-substituted uracil bases and nucleosides" *J. Org. Chem.* (1983) **48**:1854-1862	
	168	RODE "Specificity of thymidylate synthase inactivation by 4,5-bisubstituted dUMP analogues" M. Nencki Inst. Exp. Biol., *Acta Biochimica Polonica* (1993) **40(3)**:363-368	
	169	ROGULSKI et al. "Glioma cells transduced with an *Escherichia coli* CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity" *Hum. Gene Ther.* (Jan. 1, 1997) **8**:73-85	
	170	RONINSON et al. "Amplification of specific DNA sequences correlates with multi-drug resistance in Chinese hamster cells" *Nature* (June 14, 1984) **309**:626-628	
	171	RUTH and BERGSTROM "C-5 sustituted pyrimidine nucleosides. 1. Synthesis of C-5 allyl, propyl, and propenyl uracil and cytosine nucleosides via organopalladium intermediates" *J. Org. Chem.* (1978) **43(14)**:2870-2876	
	172	SANTI "Perspectives on the design and biochemical pharmacology of inhibitors of thymidylate synthetase" *J. Med. Chem.* (Feb. 1980) **23(2)**:103-111	
	173	SASTRY et al. "Membrane-permeable dideoxyuridine 5'-monophosphate analogue inhibits human immunodeficiency virus infection" *Mol. Pharmacol.* (1992) **41**:441-445	
	174	SATYAM et al. "Design, synthesis, and evaluation of latent alkylating agents activated by glutathione *S*-transferase" *J. Med. Chem.* (1996) **39**:1736-1747	
	175	SAUTER et al. "Heterogeneity of *erb*B-2 gene amplification in bladder cancer" *Cancer Res.* (May 15, 1993) **53**:2199-2203	

Examiner's Signature	E. E. Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 13 of 15

Complete if Known	
Application Number	10/048,033
Filing Date	November 28, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1615~~
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	176	SCHIFFER et al. "Crystal structure of human thymidylate synthase: A structural mechanism for guiding substrates into the active site" *Biochemistry* (1995) **34**:16279-16287	
	177	SCHIMKE "Gene amplification in cultured cells" *J. Biol.Chem.* (May 5, 1988) **263(13)**:5989-5992	
	178	SCHULTZ et al. "Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514" *Anticancer Res.* (1999) **19**:437-444	
	179	SEGOVIA "*Leishmania* gene amplification: A mechanism of drug resistance" *Ann. Trop. Med. Parasit.* (1994) **88(2)**:123-130	
	180	SHEPARD and LEWIS "Resistance of tumor cells to tumor necrosis factor" *J. Clin. Immunol.* (1988) **8(5)**:333-341	
	181	SIMON and SCHINDLER "Cell biological mechanisms of multidrug resistance in tumors" *PNAS USA* (April 1994) **91**:3497-3504	
	182	SINGH et al. "Studies on the preparation and isomeric composition of ^{186}Re- and ^{188}Re-pentavalent rhenium dimercaptosuccinic acid complex" *Nucl. Med. Commun.* (1993) **14**:197-203	
	183	SLAMON et al. "Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/*neu* oncogene" *Science* (Jan. 9, 1987) **235**:177-182	
	184	SLAMON et al. "Studies of the HER-2/*neu* proto-oncogene in human breast and ovarian cancer" *Science* (May 12, 1989) **244**:707-712	
	185	SLANSKY and FARNHAM "Transcriptional regulation of the dihydrofolate reductase gene" *BioEssays* (1996) **18(1)**:55-62	
	186	SMITH et al. "Regulation and mechanisms of gene amplification" *Phil. Trans. R. Soc. Lond. B* (1995) **347**:49-56	
	187	SNYDMAN et al. "Analysis of trends in antimicrobial resistance patterns among clinical isolates of *Bacteroides fragilis* group species from 1990 to 1994" *Clin. Infect. Dis.* (1996) **23(Suppl. 1)**:S54-S65	
	188	STASCHKE et al. "The in vitro anti-hepatitis B virus activity of FIAU [1-(2'-deoxy-2'-fluro-1-β-D-arabinofuranosyl-5-iodo)uracil] is selective, reversible, and determined, at least in part, by the host cell" *Antiviral Res.* (1994) **23**:45-61	
	189	STOUT et al. "Structure-based design of inhibitors specific for bacterial thymidylate synthase" *Biochemistry* (1999) **38**:1607-1617	
	190	STÜHLINGER et al. "Clinical therapy and HER-2 oncogene amplification in breast cancer: Chemo vs radiotherapy" *J. Steroid Biochem. Molec. Biol.* (1994) **49(1)**:39-42	
	191	SUGARMAN et al. "Recombinant human tumor necrosis factor-α: Effects on proliferation of normal and transformed cells in vitro" *Science* (Nov. 22, 1985) **230(4728)**:943-945	

Examiner's Signature	L. E. Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 14 of 15

Complete if Known	
Application Number	10/048,033
Filing Date	November 28, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1615~~
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	192	SUKUMAR and BARBACID "Specific patterns of oncogene activation in transplacentally induced tumors" *PNAS USA* (Jan. 1990) **87**:718-722	
	193	TAKEISHI et al. "Nucleotide sequence of a functional cDNA for human thymidylate synthase" *Nucl. Acid Res.* (1985) **13(6)**:2035-2043	
	194	TANNOCK "Treatment of cancer with radiation and drugs" *J. Clin. Oncol.* (Dec. 1996) **14(12)**:3156-3174	
	195	TENNANT et al. "Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection" *Hepatology* (July 1998) **28(1)**:179-191	
	196	TOLSTIKOV et al. "Synthesis and DNA duplex stabilities of oligonucleotides containing C-5-(3-methoxypropynyl)-2'-deoxyuridine residues" *Nucleos. Nucleot.* (1997) **16(3)**:215-225	
**	~~197~~	~~TOWNSEND (eds), Chemistry of Nucleosides and Nucleotides, Vol. 3, Plenum Press, New York, NY (1974) only Table of Contents, Bibliography, pages 529-535 and Index pp. 537-552 supplied~~	
	198	TROUTNER "Chemical and physical properties of radionuclides" *Nucl. Med. Biol.* (1987) **14(3)**:171-176	
	199	UBEDA and HABENER "The large subunit of the DNA replication complex C (DSEB/RF-C140) cleaved and inactivated by Caspace-3 (CPP32/YAMA) during fas-induced apoptosis" *J. Biol. Chem.* (Aug. 1, 1997) **272(31)**:19562-19568	
	200	VALETTE et al. "Decomposition pathways and *in vitro* HIV inhibitory effects of isoddA pronucleotides: Toward a rational approach for intracellular delivery of nucleoside 5'-monophosphates" *J. Med. Chem.* (1996) **39**:1981-1990	
	201	van de VIJVER et al. "Amplification of the *neu* (c-*erbB*-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-*erbA* oncogene" *Mol. Cell. Biol.* (May 1987) **7(5)**:2019-2023	
	202	van LAAR et al. "Comparision of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their role in the treatment of colorectal cancer" *European J. Cancer* (1998) **34(3)**:296-306	
	203	VOLM et al. "Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase-π in human lung tumors" *Cancer* (Aug. 15, 1992) **70(4)**:764-769	
	204	WAHBA and FRIEDKIN "Direct spectrophotometric evidence for the oxidation of tetrahydrofolate during the enzymatic synthesis of thymidylate" *J. Biol. Chem.* (Mar. 1961) **236(3)**:C11-C12	
	205	WANG et al. "Identification and characterization of Ich-3, a member of the interleukin-1β converting enzyme (ICE)/Ced-3 family and an upstream regulator of ICE" *J. Biol. Chem.* (Aug. 23, 1996) **271(34)**:20580-20587	

Examiner's Signature	L. E. Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

** Duplicate citation: see PTO-892 for citation.

10/048,033 - PTO-1449 #3 COPY FOR [ ] File [X] Applicant

PTO/SB/08b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 15 of 15

Complete if Known	
Application Number	10/048,033
Filing Date	November 28, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1615~~
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	206	WATAYA et al. "trans-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridylate: A mechanism-based inhibitor of thymidylate synthetase" *J. Med. Chem.* (Apr. 1979) **22(4)**:339-340	
	207	WATAYA et al. "Interaction of thymidylate synthetase with 5-nitro-2'-deoxyuridylate" *J. Biol. Chem.* (June 25, 1980) **255(12)**:5538-5544	
	208	WETTERGREN et al. "Drug-specific rearrangements of chromosome 12 in hydroxyurea-resistant mouse SEWA cells: Support for chromosomal breakage model of gene amplification" *Somat. Cell Molec. Gen.* (1994) **20(4)**:267-285	
	209	YEN et al. "Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine" *Cancer Res.* (July 15, 1994) **54**:3686-3691	
	210	YIN et al. "Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles" *Cell* (Sept. 18, 1992) **70**:937-948	
	211	ZHOU et al. "Target protease specificity of the viral serpin CrmA" *J. Biol. Chem.* (Mar. 21, 1997) **272(12)**:7797-7800	
	~~212~~	~~The American Heritage College Dictionary, Third Edition,~~ Houghton Mifflin Co., New York, NY (1997) only page 668 supplied	

Examiner's Signature	L. E. Crane	Date Considered	09/21/2003

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form1449A-PTO

JAN 13 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 5

Complete if Known	
Application Number	10/048,033
Filing Date	November 27, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1615~~
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number – Kind Code[2] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] – Number[4] – Kind Code[5] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
JRC	1	DE 32 29 169 A1	02-09-84	De Clercq et al.		
JRC	2	EP 0 311 107 A2	04-12-89	Stichting REGA VZW		
JRC	3	EP 0 311 108 A2	04-12-89	Stichting REGA VZW		
JRC	4	EP 0 316 592	05-24-89	Stichting REGA VZW		
**	~~5~~	~~GB 982 776~~	~~02-10-65~~	The Wellcome Foundation		
JRC	6	RO 88451	01-30-86	Antibiotics Enterprise, Iasi		X
JRC	7	WO 89/05817	06-29-89	Nucleic Acid Research Institute		
JRC	8	WO 90/03978	04-19-90	Stichting REGA VZW		
JRC	9	WO 91/17424	11-14-91	Vical, Inc.		
JRC	10	WO 92/19767	11-12-92	Terrapin Technologies, Inc.		
JRC	11	WO 93/06120	04-01-93	University of Rochester		

Examiner's Signature	L. E. Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

** Duplicate citation: see PTO-892 for citation.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 5

Complete if Known	
Application Number	10/048,033
Filing Date	November 27, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1615~~
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number – Kind Code[2] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] – Number[4] – Kind Code[5] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
JLC	12	WO 94/03467	02-17-94	Institute of Organic Chemistry & Biochemistry of the Academy of Sciences of the Czech Republic, et al.		
~~**~~	~~13~~	~~WO 94/22483~~	~~10-13-94~~	~~Kozak, Alexander~~		
JLC	14	WO 95/01806	01-19-95	Kondratyev, A.		
	~~15~~	~~WO 95/08556~~	~~03-30-95~~	~~Amersham~~ International, Inc.		
JLC	16	WO 95/12678	05-11-95	Connors, T. et al.		
~~**~~	~~17~~	~~WO 96/03151~~	~~02-08-96~~	~~Springer et al.~~		
~~**~~	~~18~~	~~WO 96/07413~~	~~04-04-96~~	University of Georgia Research Foundation & Yale University		

Examiner's Signature	L. E. Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

** Duplicate citation: see PTO-892 for citation

 COPY FOR [ ] File [X] ~~Applicant~~

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 5

Complete if Known	
Application Number	10/048,033
Filing Date	November 27, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1615~~
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number – Kind Code[2] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] – Number[4] – Kind Code[5] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
~~**~~	~~19~~	~~WO 96/10030~~	~~04-04-96~~	Isis Pharmaceuticals, Inc.		
LEC	20	WO 96/29336	09-26-96	Medical Research Council, University College Cardiff Consultants, Inc. Rega Foundation		
LEC	21	WO 96/33168	10-24-96	Kumiai Chemical Industry Co Ltd et al.		
LEC	22	WO 96/40088	12-19-96	Hostetler, Karl Y.		
	~~23~~	~~WO 96/40708~~	~~12-19-96~~	La Jolla Pharmaceuticals, Inc.		
LEC	24	WO 96/40739	12-19-96	Terrapin Technologies, Inc.		
LEC	25	WO 97/25342	07-17-97	Terrapin Technologies, Inc.		

Examiner's Signature	L. E. Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

** Duplicate citation: see PTO-892 for citaiton.

 COPY FOR [ ] File [X] ~~Applicant~~

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 5

Complete if Known	
Application Number	10/048,033
Filing Date	November 27, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1615~~
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number – Kind Code[2] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3] – Number[4] – Kind Code[5] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
**	~~26~~	~~WO 97/28179~~	~~08-07-97~~	Fick, James & Israel, Mark		
JRC	27	WO 97/49717	12-31-97	Balzarini et al.		
JRC	28	WO 98/49177	11-05-98	University College Cardiff Consultants Limited		
JRC	29	WO 99/06072	02-11-99	Boehringer Mannheim Corp.		
**	~~30~~	~~WO 99/20741~~	~~04-29-99~~	~~Geron Corporation~~		
JRC	31	WO 99/23104	05-14-99	The Government of the United States of America represented by The Secretary of Health & Human Services		

Examiner's Signature	L. E. Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

If you need assistance in completing this form, call 1-800-PTO-9199 and select option 2.

** Duplicate citation: see PTO-892 for citation.

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 5

Complete if Known	
Application Number	10/048,033
Filing Date	November 27, 2002
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1645~~
Examiner Name	Not Yet Assigned
Attorney Docket Number	NB 2006.01

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number – Number – Kind Code[2] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document – Country Code[3] – Number[4] – Kind Code[5] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
MRC	32	WO 99/37753	07-29-99	NewBiotics, Inc.		
MRC	33	WO 00/18775	04-06-00	University College Cardiff Consultants Limited and Rega Foundation		
	34	WO 00/33888	06-15-00	Dubois, V. et al.		
	35	WO 01/07088	02-01-01	NewBiotics, Inc.		
	36	WO 01/83501	11-08-01	University College Cardiff Consultants Limited and Rega Foundation		
MRC	37	WO 01/85749	11-15-01	University College Cardiff Consultants Limited and Rega Foundation		

Examiner's Signature	L. E. Crane	Date Considered	09/21/2005

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

COPY FOR [ ] File [X] Applicant

ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

Title of Invention	METHODS FOR TREATING THERAPY-RESISTANT TUMORS

Application Number: 10/048033

Confirmation Number: 2767

First Named Applicant: H. SHEPARD

Attorney Docket Number: NB 2006.01

Art Unit: ~~1615~~ 1623

Examiner: Not Yet Assigned

Search string: (3852266 or 4247544 or 4267171 or 4542210 or 4668777 or 4816570 or 4948882 or 4963263 or 4963533 or 4975278 or 5070082 or 5077282 or 5077283 or 5085983 or 5116822 or 5116827 or 5133866 or 5137724 or 5212161 or 5212291 or 5217869 or 5233031 or 5264618 or 5300425 or 5338659 or 5430148 or 5433955 or 5457187 or 5459127 or 5516631 or 5521161 or 5527900 or 5596018 or 5616564 or 5627165 or 5645988 or 5663321 or 5733896 or 5798340 or 5968910 or 5981507 or 6057305 or 6245750 or 6339151 or 6495553 or 20010034440).pn

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass
~~**~~	~~1~~	~~3852266~~	~~1974-12-03~~	~~Kiyanagi~~ et al.			
	2	4247544	1981-01-27	Bergstrom et al.			
	3	4267171	1981-04-12	Bergstrom et al.			
	4	4542210	1985-09-17	Sakata et al.			
	5	4668777	1987-05-26	Caruthers et al.			
	6	4816570	1989-03-28	Farquhar			
	7	4948882	1990-08-14	Ruth			
	8	4963263	1990-10-16	Kauvar			
	9	4963533	1990-10-16	de Clercq et al.			
	10	4975278	1990-12-04	Senter et al.			
~~**~~	~~11~~	~~5070082~~	~~1991-12-03~~	~~Murdock~~ et al.			
~~**~~	~~12~~	~~5077282~~	~~1991-12-31~~	~~Murdock~~ et al.			
~~**~~	~~13~~	~~5077283~~	~~1991-12-31~~	~~Murdock~~ et al.			
	14	5085983	1992-02-04	Scanlon			
	15	5116822	1992-05-26	De Clercq et al.			
~~**~~	~~16~~	~~5116827~~	~~1992-05-26~~	~~Murdock~~ et al.			
	17	5133866	1992-07-28	Kauvar			
	18	5137724	1992-08-11	Balzarini et al.			
~~**~~	~~19~~	~~5212161~~	~~1993-05-18~~	~~Moriniere~~ et al.			

Examiner Name	Date
L.E. CRANE	09/21/2005

** Duplicate citations: see PTO-892 for citations.

ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic V[redacted]n v18

Stylesheet Version v18.0

p. 2 of 2

Title of Invention	METHODS FOR TREATING THERAPY-RESISTANT TUMORS

Application Number: 10/048033

Confirmation Number: 2767

First Named Applicant: H. SHEPARD

Attorney Docket Number: NB 2006.01

Art Unit: ~~1615~~ 1623

Examiner: Not Yet Assigned

~~**~~	~~20~~	~~5212291~~	~~1993-05-18~~	~~Murdock et al.~~				
	21	5217869	1993-06-08	Kauvar				
	22	5233031	1993-08-03	Borch et al.				
	23	5264618	1993-11-23	Felgner et al.				
	24	5300425	1994-04-05	Kauvar				
	25	5338659	1994-08-16	Kauvar et al.				
	26	5430148	1995-07-04	Webber et al.				
	27	5433955	1995-07-18	Bredehorst et al.				
~~**~~	~~28~~	~~5457187~~	~~1995-10-10~~	~~Gmeiner et al.~~				
	29	5459127	1995-10-17	Felgner et al.				
	30	5516631	1996-05-14	Frisch				
	31	5521161	1996-05-28	Malley et al.				
	32	5527900	1996-06-18	Balzarini et al.				
	33	5596018	1997-01-21	Baba et al.				
~~**~~	~~34~~	~~5616564~~	~~1997-04-01~~	~~Rapaport et al.~~				
	35	5627165	1997-05-06	Glazier				
	36	5645988	1997-07-08	Vande Woude et al.				
	37	5663321	1997-09-02	Gmeiner et al.				
	38	5733896	1998-03-31	Holy et al.				
	39	5798340	1998-08-25	Bischofberger et al.				
	40	5968910	1999-10-19	Balzarini				
	41	5981507	1999-11-09	Josephson et al.				
	42	6057305	2000-05-02	Holy et al.				
~~**~~	~~43~~	~~6245750~~	~~2001-06-12~~	~~Shepard~~				
~~**~~	~~44~~	~~6339151~~	~~2002-02-15~~	~~Shepard et al.~~				
~~**~~	~~45~~	~~6495553~~	~~2002-12-17~~	~~Shepard~~				

** Duplicate citations: see PTO-892 for citations.

US Published Applications

Note: Applicant is not required to submit a paper copy of cited US Published Applications

init	Cite.No.	Pub. No.	Date	Applicant	Kind	Class	Subclass
~~SS~~	~~1~~	~~20010034440~~	~~2001-10-25~~	~~Shepard et al.~~			

Signature

Examiner Name	Date
L.E. CRANE	09/21/2005

** Duplicate citations: see PTO-892 for citations.